Increased serum FSH in female fragile X premutation carriers with either regular menstrual cycles or on oral contraceptives

被引:68
作者
Hundscheid, RDL
Braat, DDM
Kiemeney, LALM
Smits, APT
Thomas, CMG
机构
[1] Univ Nijmegen, Med Ctr, Dept Chem Endocrinol, NL-6500 HB Nijmegen, Netherlands
[2] Univ Nijmegen, Med Ctr, Dept Obstet & Gynaecol, NL-6500 HB Nijmegen, Netherlands
[3] Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands
[4] Univ Nijmegen, Med Ctr, Dept Epidemiol, NL-6500 HB Nijmegen, Netherlands
关键词
diminished ovarian reserve; fragile X premutation; FSH; inhibin B; premature ovarian failure;
D O I
10.1093/humrep/16.3.457
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Fragile X premutations are known to be a risk factor for diminished ovarian function at a relatively young age, We studied endocrine profiles of female fragile X family members (n = 79) at risk of premature ovarian failure (POF), Of these 79 women aged <40 years, 45 had menstrual cycles, and 34 were using oral contraceptives, Of the women with menstrual cycles, the premutation carriers had higher serum FSH concentrations than women who were not carrying the premutation, Even premutation carriers with regular cycles showed increased serum FSH concentrations. Moreover, premutation carriers using oral contraceptives also demonstrated increased serum FSH concentrations. Irrespective of whether oral contraceptives were used, a serum FSH concentration of <greater than or equal to>15 IU/l was more common in the premutation carriers than in the other women. One premutation carrier using oral contraceptives had a serum FSH concentration of >40 IU/l, the threshold that defines POF. We confirmed that premutation carriers with menstrual cycles demonstrate premature ovarian dysfunction, However, we also found endocrine signs of unrecognized ovarian dysfunction in premutation carriers using oral contraceptives, despite endocrine alterations by oral contraceptives. Premutation carriers may have a poorer prognosis for future pregnancy, either achieved spontaneously or by assisted reproductive technology. We recommend that premutation carriers should be counselled not to wait too long if they wish to start a family.
引用
收藏
页码:457 / 462
页数:6
相关论文
共 28 条
[1]  
Allingham-Hawkins SJ, 1999, AM J MED GENET, V83, P322, DOI 10.1002/(SICI)1096-8628(19990402)83:4<322::AID-AJMG17>3.0.CO
[2]  
2-B
[3]  
Braat DDM, 1999, AM J MED GENET, V83, P327, DOI 10.1002/(SICI)1096-8628(19990402)83:4<327::AID-AJMG19>3.0.CO
[4]  
2-R
[5]   FURTHER-STUDIES ON PITUITARY AND OVARIAN-FUNCTION IN WOMEN RECEIVING HORMONAL CONTRACEPTION [J].
COHEN, BL ;
KATZ, M .
CONTRACEPTION, 1981, 24 (02) :159-172
[6]   PITUITARY AND OVARIAN-FUNCTION IN WOMEN RECEIVING HORMONAL CONTRACEPTION [J].
COHEN, BL ;
KATZ, M .
CONTRACEPTION, 1979, 20 (05) :475-487
[7]   Inhibin-B as a test of ovarian reserve for infertile women [J].
Corson, SL ;
Gutmann, J ;
Batzer, FR ;
Wallace, H ;
Klein, N ;
Soules, MR .
HUMAN REPRODUCTION, 1999, 14 (11) :2818-2821
[8]   Laboratory criteria for menopause in women using oral contraceptives [J].
Creinin, MD .
FERTILITY AND STERILITY, 1996, 66 (01) :101-104
[9]   Day 3 serum inhibin B and FSH and age as predictors of assisted reproduction treatment outcome [J].
Creus, M ;
Peñarrubia, J ;
Fábregues, F ;
Vidal, E ;
Carmona, F ;
Casamitjana, R ;
Vanrell, JA ;
Balasch, J .
HUMAN REPRODUCTION, 2000, 15 (11) :2341-2346
[10]   Effect of smoking on ovarian reserve and ovarian stimulation in in-vitro fertilization and embryo transfer [J].
El-Nemr, A ;
Al-Shawaf, T ;
Sabatini, L ;
Wilson, C ;
Lower, AM ;
Grudzinskas, JG .
HUMAN REPRODUCTION, 1998, 13 (08) :2192-2198